Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZT vs ddI vs AZT+ddI in Symptomatic HIV-Infected Children
NCT00000637Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Zidovudine (AZT) Monotherapy, Didanosine (ddI) Monotherapy and AZT + ddI Combination (3 arms). Primary endpoints: Overall Survival and Time to Disease Progression. Status: completed.
02
Drugs
zidovudinedidanosine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00000637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000637.